Harmony Biosciences
HRMY
279 hedge funds and large institutions have $1.62B invested in Harmony Biosciences in 2025 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 127 increasing their positions, 70 reducing their positions, and 31 closing their positions.
366% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $2.26M
81% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 70
26% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 31
3% more funds holding
Funds holding: 272 → 279 (+7)
1.59% more ownership
Funds ownership: 87.66% → 89.25% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $1.67B → $1.62B (-$47.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$19.5M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$16.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2M |
| 4 |
Goldman Sachs
New York
|
+$12.1M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$27.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$21M |
| 3 |
NVCHI
New Vernon Capital Holdings II
Morristown,
New Jersey
|
-$15.2M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$10.3M |
| 5 |
JP Morgan Chase
New York
|
-$9.36M |
HRMY Hedge Fund Activity: Q2 2025 in Review
279 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2025, worth a combined $1.62B — down 2.8% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new HRMY positions and 31 closed out — a net gain of 8 holders — while 127 added to existing stakes and 70 trimmed.
The largest buyer was Boston Partners, opening a new position worth an estimated $19.5M. The largest seller was Citadel Advisors, exiting entirely with an estimated $27.7M sold.
- 279 institutional investors held Harmony Biosciences (HRMY) as of Q2 2025, up from 272 in Q1 2025.
- Funds reported $1.62B of Harmony Biosciences stock for Q2 2025, down 2.8% quarter-over-quarter.
- 39 funds opened new Harmony Biosciences positions in Q2 2025 and 31 closed out, a net change of +8 holders.
- The largest Harmony Biosciences buyer in Q2 2025 was Boston Partners, an estimated $19.5M added.
- The largest Harmony Biosciences seller in Q2 2025 was Citadel Advisors, an estimated $27.7M sold.
Based on aggregated 13F filings for Q2 2025.